Prof. Dr. Hanno Wild Bayer Schering Pharma AG Head of Global Lead Generation & Optimization Basle, October 08, 2009 Succes...
Challenges for the entire pharmaceutical industry Unprecedented change around the globe   <ul><li>Regulatory and safety co...
Challenges for R&D Key reactions of Bayer/Bayer Schering Pharma - strong need for continuous steering <ul><li>Portfolio  a...
Bayer Schering Pharma*  Key Data Specialty Medicine Diagnostic Imaging General Medicine Women’s Healthcare * USA/Canada: B...
Bayer Schering Pharma’s R&D strategy  Key factors to increase  Productivity 4 therapeutic research areas with activities f...
Bayer Schering Pharma’s  R&D Strategy Focus on Four Therapeutic Research Areas Bayer Schering June 2005 Oncology Cardiolog...
Bayer Schering Pharma’s  R&D Strategy Focus combined with selected opportunities <ul><li>Focus indications </li></ul><ul><...
Bayer Schering Pharma’s R&D Pipeline A balanced mix of NME and LCM opportunities Status as of July 2009  Phase II (17) Pha...
At the end, however, this is not a numbers game…  …  more focus: <ul><li>Stringent quality criteria </li></ul><ul><li>Cons...
 
Forward-Looking Statements This presentation may contain forward-looking statements based on current assumptions and forec...
Bayer Schering Pharma Top 10 Products Product [EUR million] 2007 2008 YAZ ®   /   Yasmin ®   /   Yasminelle ®  (Women’s He...
Upcoming SlideShare
Loading in …5
×

1 1 Innovation Wild

1,868 views

Published on

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
1,868
On SlideShare
0
From Embeds
0
Number of Embeds
110
Actions
Shares
0
Downloads
33
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

1 1 Innovation Wild

  1. 1. Prof. Dr. Hanno Wild Bayer Schering Pharma AG Head of Global Lead Generation & Optimization Basle, October 08, 2009 Successful innovation within a post-merger environment
  2. 2. Challenges for the entire pharmaceutical industry Unprecedented change around the globe <ul><li>Regulatory and safety concerns </li></ul><ul><li>Generics often first line therapy </li></ul><ul><li>Pricing pressures </li></ul><ul><li>Payers eclipsing doctors as decision makers </li></ul><ul><li>Shifting portfolios from primary care to specialist-driven therapies </li></ul><ul><li>Current economic crisis is reinforcing the trends in the markets </li></ul>Environmental Pressures <ul><li>Outsourcing and labor reduction to reduce costs </li></ul><ul><li>Entry into new markets – biosimilars, services </li></ul><ul><li>Focus on pharmerging markets </li></ul><ul><li>M&A to enhance the pipeline and reduce cost </li></ul><ul><li>Redesigning the commercial model </li></ul>Industry Challenges <ul><li>Continuously rising investments </li></ul><ul><li>Higher attrition rates = lower number on NMEs </li></ul><ul><li>Increasing hurdles regarding efficacy & safety </li></ul><ul><li>Low hanging fruits have been picked </li></ul><ul><li>Innovation crisis? </li></ul>Challenges for R&D
  3. 3. Challenges for R&D Key reactions of Bayer/Bayer Schering Pharma - strong need for continuous steering <ul><li>Portfolio adjustments  Bayer Pharma 2002-2005 </li></ul><ul><li>Mergers & Acquisitions  Schering Integration 2006 - 2008 </li></ul><ul><li>Efficiency  Internal program 2009 - 2012 </li></ul><ul><ul><ul><ul><ul><li>Further increase R&D productivity and innovation, </li></ul></ul></ul></ul></ul><ul><ul><ul><ul><ul><li>Optimize internal processes and resource allocation </li></ul></ul></ul></ul></ul><ul><ul><ul><ul><ul><li>Complement internal activities by innovation sourcing </li></ul></ul></ul></ul></ul>
  4. 4. Bayer Schering Pharma* Key Data Specialty Medicine Diagnostic Imaging General Medicine Women’s Healthcare * USA/Canada: Bayer HealthCare Pharmaceuticals Among the top 10 specialty pharma companies worldwide Focus on 4 major business units Sales 2008: EUR10,704 million Investments in R&D: mid term 15 – 17 % of total net sales
  5. 5. Bayer Schering Pharma’s R&D strategy Key factors to increase Productivity 4 therapeutic research areas with activities from target discovery up to launch (reduced from 8) 1 … more focus: Increase in development candidate output at decreased cost per NME (global use of platforms, stringent resource allocation, site consolidation) 2 … higher efficiency: Common mechanism approach to utilize opportunities 4 … value maximization: NME: New Molecular Entity Proof-of-Concept approach and strict project progression criteria 3 … better quality:
  6. 6. Bayer Schering Pharma’s R&D Strategy Focus on Four Therapeutic Research Areas Bayer Schering June 2005 Oncology Cardiology Hematology Oncology Gynecology Immunology Dermatology Andrology Diagnostic Imaging Bayer Schering Pharma June 2007 Cardiology Diagnostic Imaging Women’s Healthcare Oncology June 1999 Bayer Schering Oncology Cardiology Hematology Oncology Gynecology, FC MM Immunology/Inflam. Dermatology Andrology Cardiology Diabetes/Obesity COPD/Asthma Gene Therapy Diagnostic Imaging
  7. 7. Bayer Schering Pharma’s R&D Strategy Focus combined with selected opportunities <ul><li>Focus indications </li></ul><ul><li>Research centered in Germany: Berlin & Wuppertal </li></ul><ul><li>Core competencies (e.g. Screening, MedChem, Pharmacology, Toxicology) </li></ul><ul><li>Specialty indications </li></ul>Focus <ul><li>Common mechanism research </li></ul><ul><li>Innovation centers US & China </li></ul><ul><li>Strategy for innovation sourcing </li></ul><ul><li>Expansion from specialty to larger indications </li></ul><ul><li>R&D for pharmerging markets </li></ul>Opportunities & Berlin Wuppertal US West Coast Main Sites Employees in R&D 5,912 (as of Dec. 31, 2007) Beijing Global Drug Discovery Innovation Centers
  8. 8. Bayer Schering Pharma’s R&D Pipeline A balanced mix of NME and LCM opportunities Status as of July 2009 Phase II (17) Phase III (18) Medical ill Xarelto ® SPAF Xarelto ® VTE Treatment Xarelto ® wet AMD VEGF Trap-Eye CRVO VEGF Trap-Eye PAH Riociguat (sGC Stimulator) CTEPH Riociguat (sGC Stimulator) ACS Xarelto ® Acute Heart Failure Cinaciguat (sGC Activator) DME VEGF Trap-Eye PH in COPD / ILD Riociguat (sGC Stimulator) 2nd line Breast Cancer Lonaprisan (ZK-PRA) Lung / Ovar / Prostate Sagopilone (ZK-EPO) Alzheimer PET Imaging BAY94-9172 (AV1 / ZK) Cancer DAST Inh. (BAY73-4506) Liposomal Formulation Kogenate ® Breast Cancer Nexavar ® Ovarian or Peritoneal Cancer Nexavar ® Colorectal Cancer Nexavar ® Additional Indications Nexavar ® Lung Infection Cipro ® inhale Oral Contraception E2+DRSP Oral Contraception OC+DHEA Oral Contraception Valette plus Gram-neg. Pneumonia Amikacin inhale NSCLC Nexavar ® Multiple Sclerosis Alemtuzumab Bone Met. Prev. Breast Cancer Bonefos ® Dysmenorrhea (J) YAZ ® Oral Contraception YAZ ® Flex Oral Contraception Yasmin ® plus / YAZ ® plus Menopause Management Angeliq low-low Contraception LCS (ULD LNG) ACS Aspirin ® i.v. Contraception FC Patch Low Phase I (8) PH in COPD Elastase Inhibitor Cancer L19-SIP Colorectal Cancer L19-TNFalpha Gastro IBD Lipoxin Cancer MN Immunoconjugate Cancer PI3K Inhibitor Cancer MEK- Inhibitor Hemophilia rec. Factor VII Despite the challenges to R&D, Bayer Schering Pharma brought a constant flow of NMEs to the market while reducing its cost basis New Molecular Entities (NME) Life Cycle Management (LCM)
  9. 9. At the end, however, this is not a numbers game… … more focus: <ul><li>Stringent quality criteria </li></ul><ul><li>Consistency of strategies </li></ul><ul><li>Flexible responses to new findings </li></ul><ul><li>Transparent decision making and communication </li></ul><ul><li>Talented people </li></ul>… it is about
  10. 11. Forward-Looking Statements This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
  11. 12. Bayer Schering Pharma Top 10 Products Product [EUR million] 2007 2008 YAZ ® / Yasmin ® / Yasminelle ® (Women’s Healthcare) 1,042 1,222 Betaferon ® / Betaseron ® (Specialty Medicine) 1,028 1,144 Kogenate ® (Specialty Medicine) 818 848 Adalat ® (General Medicine) 614 626 Avalox ® / Avelox ® (General Medicine) 445 462 Nexavar ® (Specialty Medicine) 270 462 Mirena ® (Women’s Healthcare) 361 462 Levitra ® (General Medicine) 332 341 Cipro ® / Ciprobay ® (General Medicine) 383 338 Glucobay ® (General Medicine) 298 304

×